Spotlight on Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®) in the Prevention of Premalignant Genital Lesions, Genital Cancer, and Genital Warts in Women

被引：0

作者：

Paul L. McCormack

Elmar A. Joura

机构：

[1] Adis,Department of Obstetrics and Gynaecology, Division of Gynaecologic Oncology

[2] a Wolters Kluwer Business,undefined

[3] Medical University of Vienna,undefined

来源：

BioDrugs | 2011年 / 25卷

关键词：

Human Papilloma Virus; Genital Wart; Seroconversion Rate; Human Papilloma Virus Vaccine; Human Papilloma Virus Type;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Quadrivalent human papilloma virus (HPV) [types 6, 11, 16, 18] recombinant vaccine (Gardasil®; Silgard®) is composed of virus-like particles (VLPs) formed by self-assembly of recombinant L1 capsid protein from each of HPV types 6, 11, 16, and 18. The VLPs are noninfectious, containing no DNA, and are highly immunogenic, inducing high levels of neutralizing antibodies against the particular HPV types when administered to animals or humans. Quadrivalent HPV vaccine is indicated for use from the age of 9 years for the prevention of premalignant genital lesions (cervical, vulvar, and vaginal), cervical cancer, and external genital warts (condyloma acuminata) causally related to certain oncogenic or specific HPV types.

引用

页码：339 / 343

页数：4

共 42 条

[31] Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years
Einstein, Mark H.
Baron, Mira
Levin, Myron J.
Chatterjee, Archana
Fox, Bradley
Scholar, Sofia
Rosen, Jeffrey
Chakhtoura, Nahida
Lebacq, Marie
van der Most, Robbert
Moris, Philippe
Giannini, Sandra L.
Schuind, Anne
Datta, Sanjoy K.
Descamps, Dominique
HUMAN VACCINES, 2011, 7 (12): : 1359 - 1373
[32] High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
L L Villa
R L R Costa
C A Petta
R P Andrade
J Paavonen
O-E Iversen
S-E Olsson
J Høye
M Steinwall
G Riis-Johannessen
A Andersson-Ellstrom
K Elfgren
G von Krogh
M Lehtinen
C Malm
G M Tamms
K Giacoletti
L Lupinacci
R Railkar
F J Taddeo
J Bryan
M T Esser
H L Sings
A J Saah
E Barr
British Journal of Cancer, 2006, 95 : 1459 - 1466
[33] High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
Villa, L. L.
Costa, R. L. R.
Petta, C. A.
Andrade, R. P.
Paavonen, J.
Iversen, O-E
Olsson, S-E
Hoye, J.
Steinwall, M.
Riis-Johannessen, G.
Andersson-Ellstrom, A.
Elfgren, K.
von Krogh, G.
Lehtinen, M.
Malm, C.
Tamms, G. M.
Giacoletti, K.
Lupinacci, L.
Railkar, R.
Taddeo, F. J.
Bryan, J.
Esser, M. T.
Sings, H. L.
Saah, A. J.
Barr, E.
BRITISH JOURNAL OF CANCER, 2006, 95 (11) : 1459 - 1466
[34] Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects
Kang, S.
Kim, K. H.
Kim, Y. T.
Kim, Y. T.
Kim, J. H.
Song, Y. S.
Shin, S. H.
Ryu, H. S.
Han, J. W.
Kang, J. H.
Park, S. Y.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (05) : 1013 - 1019
[35] Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, double-blind, placebo-controlled trial in Chinese males and females
Li, Rongcheng
Li, Yanping
Radley, David
Liu, Youping
Huang, Teng
Sings, Heather L.
Zhang, Lingling
Wang, Wei
Zhong, Xiang
Saah, Alfred J.
VACCINE, 2012, 30 (28) : 4284 - 4291
[36] Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine
Block, Stan L.
Brown, Darron R.
Chatterjee, Archana
Gold, Michael A.
Sings, Heather L.
Meibohm, Anne
Dana, Adrian
Haupt, Richard M.
Barr, Eliav
Tamms, Gretchen M.
Zhou, Haiping
Reisinger, Keith S.
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2010, 29 (02) : 95 - 101
[37] Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine Follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years
Einstein, Mark H.
Baron, Mira
Levin, Myron J.
Chatterjee, Archana
Fox, Bradley
Scholar, Sofia
Rosen, Jeffrey
Chakhtoura, Nahida
Meric, Dorothee
Dessy, Francis J.
Datta, Sanjoy K.
Descamps, Dominique
Dubin, Gary
HUMAN VACCINES, 2011, 7 (12): : 1343 - 1358
[38] Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
Einstein, Mark H.
Takacs, Peter
Chatterjee, Archana
Sperling, Rhoda S.
Chakhtoura, Nahida
Blatter, Mark M.
Lalezari, Jacob
David, Marie-Pierre
Lin, Lan
Struyf, Frank
Dubin, Gary
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (12) : 3435 - 3445
[39] Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: Follow-up through Month 48 in a Phase III randomized study
Einstein, Mark H.
Levin, Myron J.
Chatterjee, Archana
Chakhtoura, Nahida
Takacs, Peter
Catteau, Gregory
Dessy, Francis J.
Moris, Philippe
Lin, Lan
Struyf, Frank
Dubin, Gary
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (12) : 3455 - 3465
[40] Immunogenicity and safety of two novel human papillomavirus 4-and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial
Shu, Yajun
Yu, Yebin
Ji, Ying
Zhang, Li
Li, Yuan
Qin, Haiyang
Huang, Zhuhang
Ou, Zhiqiang
Huang, Meilian
Shen, Qiong
Li, Zehong
Hu, Meng
Li, Chunyun
Zhang, Gaoxia
Zhang, Jikai
VACCINE, 2022, 40 (48) : 6947 - 6955

← 1 2 3 4 5 →